Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.39 |
| ▸ | PPARG | P37231 | 5/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 8/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753792 | 0.90 | MDM2 (0.40) | EPHX2PPARGMDM2MEN1MAPT | |
| SCHEMBL5754407 | 0.85 | PPARG (0.45) | EPHX2PPARGMDM2MEN1MAPT | |
| SCHEMBL5749378 | 0.83 | MDM2 (0.48) | MDM2MEN1MAPTCASP3KMT2A | |
| SCHEMBL5749716 | 0.81 | MDM2 (0.39) | EPHX2PPARGMDM2MEN1MAPT | |
| SCHEMBL5750535 | 0.80 | PPARG (0.34) | EPHX2PPARGMEN1MAPTKMT2A | |
| SCHEMBL5748807 | 0.80 | EPHX2 (0.54) | EPHX2PPARGMDM2MEN1MAPT | |
| SCHEMBL5750115 | 0.78 | PPARG (0.46) | EPHX2PPARGMDM2MAPTALDH1A1 | |
| SCHEMBL5753349 | 0.78 | EPHX2 (0.54) | EPHX2PPARGMDM2MEN1MAPT | |
| SCHEMBL5750829 | 0.78 | MDM2 (0.44) | EPHX2PPARGMDM2MEN1MAPT | |
| SCHEMBL5751165 | 0.78 | PPARG (0.54) | EPHX2PPARGMDM2MAPTPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | EPHX2 1434/4885PPARG 905/4885MDM2 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.